Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1968 3
1979 1
1980 3
1982 2
1986 3
1987 1
1990 1
1991 3
1992 2
1993 1
1994 1
1996 3
1998 1
2001 1
2002 2
2003 1
2004 5
2005 7
2006 3
2007 16
2008 7
2009 2
2010 6
2011 15
2012 13
2013 15
2014 21
2015 9
2016 19
2017 25
2018 22
2019 25
2020 37
2021 47
2022 62
2023 36
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

379 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Almshety
Page 1
The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, Tudur-Smith C, Plumpton C, Hughes DA, Williamson P, Baker GA, Balabanova S, Taylor C, Brown R, Hindley D, Howell S, Maguire M, Mohanraj R, Smith PE; SANAD II collaborators. Marson A, et al. Lancet. 2021 Apr 10;397(10282):1375-1386. doi: 10.1016/S0140-6736(21)00246-4. Lancet. 2021. PMID: 33838758 Free PMC article. Clinical Trial.
For participants aged 12 years or older, the initial advised maintenance doses were 500 mg twice per day for levetiracetam and valproate, and for children aged 5-12 years, the initial daily maintenance doses advised were 25 mg/kg for valproate and 40 mg/kg for levetiracetam. All …
For participants aged 12 years or older, the initial advised maintenance doses were 500 mg twice per day for levetiracetam and valproate, an …
The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, Tudur-Smith C, Plumpton C, Hughes DA, Williamson P, Baker GA, Balabanova S, Taylor C, Brown R, Hindley D, Howell S, Maguire M, Mohanraj R, Smith PE; SANAD II collaborators. Marson A, et al. Lancet. 2021 Apr 10;397(10282):1363-1374. doi: 10.1016/S0140-6736(21)00247-6. Lancet. 2021. PMID: 33838757 Free PMC article. Clinical Trial.
Participants and investigators were not masked and were aware of treatment allocation. SANAD II was designed to assess non-inferiority of both levetiracetam and zonisamide to lamotrigine for the primary outcome of time to 12-month remission. ...
Participants and investigators were not masked and were aware of treatment allocation. SANAD II was designed to assess non-inferiorit …
The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial.
Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR; SANAD Study group. Marson AG, et al. Lancet. 2007 Mar 24;369(9566):1016-26. doi: 10.1016/S0140-6736(07)60461-9. Lancet. 2007. PMID: 17382828 Free PMC article. Clinical Trial.
Lamotrigine and topiramate are also thought to possess broad spectrum activity. The SANAD study aimed to compare the longer-term effects of these drugs in patients with generalised onset seizures or seizures that are difficult to classify. METHODS: SANAD was an unbl …
Lamotrigine and topiramate are also thought to possess broad spectrum activity. The SANAD study aimed to compare the longer-term effe …
Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
Marson AG, Burnside G, Appleton R, Smith D, Leach JP, Sills G, Tudur-Smith C, Plumpton CO, Hughes DA, Williamson PR, Baker G, Balabanova S, Taylor C, Brown R, Hindley D, Howell S, Maguire M, Mohanraj R, Smith PE. Marson AG, et al. Health Technol Assess. 2021 Dec;25(75):1-134. doi: 10.3310/hta25750. Health Technol Assess. 2021. PMID: 34931602 Free article. Clinical Trial.
CONCLUSIONS: Focal epilepsy - The SANAD II findings do not support the use of levetiracetam or zonisamide as first-line treatments in focal epilepsy. Generalised and unclassifiable epilepsy - The SANAD II findings do not support the use of levetiracetam as a first-l …
CONCLUSIONS: Focal epilepsy - The SANAD II findings do not support the use of levetiracetam or zonisamide as first-line treatments in …
Sanadset 650K: Data on Hadith narrators.
Mghari M, Bouras O, El Hibaoui A. Mghari M, et al. Data Brief. 2022 Aug 17;44:108540. doi: 10.1016/j.dib.2022.108540. eCollection 2022 Oct. Data Brief. 2022. PMID: 36065202 Free PMC article.
The chain of narrators (Sanad) plays a vital role in deciding the authenticity of Islamic hadiths. ...Automated Sanad evaluation using machine learning algorithms is the best way to solve this problem. ...
The chain of narrators (Sanad) plays a vital role in deciding the authenticity of Islamic hadiths. ...Automated Sanad evaluati …
Editorial: Food safety and public health.
Helmy YA, El-Adawy H, Sanad YM, Ghanem M. Helmy YA, et al. Front Microbiol. 2023 Mar 9;14:1169139. doi: 10.3389/fmicb.2023.1169139. eCollection 2023. Front Microbiol. 2023. PMID: 36970698 Free PMC article. No abstract available.
Accessory Nerve Injury.
AlShareef S, Newton BW. AlShareef S, et al. 2022 Dec 19. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2022 Dec 19. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 30335278 Free Books & Documents.
SANAD II: Dear Levetiracetam, the Honeymoon Is Over.
Bermeo-Ovalle A. Bermeo-Ovalle A. Epilepsy Curr. 2021 Dec 31;22(1):18-21. doi: 10.1177/15357597211052129. eCollection 2022 Jan-Feb. Epilepsy Curr. 2021. PMID: 35233190 Free PMC article. No abstract available.
379 results